| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2327 | 2017 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1820 | 2017 |
| Artificial intelligence in cancer imaging: clinical challenges and applications WL Bi, A Hosny, MB Schabath, ML Giger, NJ Birkbak, A Mehrtash, ... CA: a cancer journal for clinicians 69 (2), 127-157, 2019 | 1566 | 2019 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1268 | 2017 |
| Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition K Litchfield, JL Reading, C Puttick, K Thakkar, C Abbosh, R Bentham, ... Cell 184 (3), 596-614. e14, 2021 | 681 | 2021 |
| Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic A Sud, ME Jones, J Broggio, C Loveday, B Torr, A Garrett, DL Nicol, ... Annals of Oncology 31 (8), 1065-1074, 2020 | 613 | 2020 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 582 | 2018 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 445 | 2017 |
| Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021 | 442 | 2021 |
| Lung adenocarcinoma promotion by air pollutants W Hill, EL Lim, CE Weeden, C Lee, M Augustine, K Chen, FC Kuan, ... Nature 616 (7955), 159-167, 2023 | 367 | 2023 |
| Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection C Abbosh, NJ Birkbak, C Swanton Nature Reviews Clinical Oncology 15 (9), 577-586, 2018 | 359 | 2018 |
| Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse F Chemi, DG Rothwell, N McGranahan, S Gulati, C Abbosh, SP Pearce, ... Nature medicine 25 (10), 1534-1539, 2019 | 187 | 2019 |
| Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie, A Rowan, ... Cancer cell 39 (11), 1497-1518. e11, 2021 | 186 | 2021 |
| Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA C Abbosh, AM Frankell, T Harrison, J Kisistok, A Garnett, L Johnson, ... Nature 616 (7957), 553-562, 2023 | 150 | 2023 |
| The evolution of lung cancer and impact of subclonal selection in TRACERx AM Frankell, M Dietzen, M Al Bakir, EL Lim, T Karasaki, S Ward, ... Nature 616 (7957), 525-533, 2023 | 147 | 2023 |
| Antibodies against endogenous retroviruses promote lung cancer immunotherapy KW Ng, J Boumelha, KSS Enfield, J Almagro, H Cha, O Pich, T Karasaki, ... Nature 616 (7957), 563-573, 2023 | 132 | 2023 |
| Embracing cancer complexity: Hallmarks of systemic disease C Swanton, E Bernard, C Abbosh, F André, J Auwerx, A Balmain, ... Cell 187 (7), 1589-1616, 2024 | 101 | 2024 |
| A clonal expression biomarker associates with lung cancer mortality D Biswas, NJ Birkbak, R Rosenthal, CT Hiley, EL Lim, K Papp, S Boeing, ... Nature medicine 25 (10), 1540-1548, 2019 | 97 | 2019 |
| The evolution of non-small cell lung cancer metastases in TRACERx M Al Bakir, A Huebner, C Martínez-Ruiz, K Grigoriadis, TBK Watkins, ... Nature 616 (7957), 534-542, 2023 | 95 | 2023 |
| Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses C Abbosh, C Swanton, NJ Birkbak Annals of Oncology 30 (3), 358-359, 2019 | 74 | 2019 |
